## Core Concept
The initiation of beta-blocker therapy in patients with congestive heart failure (CHF) requires careful consideration due to the potential for initial worsening of heart failure symptoms. Beta-blockers are a cornerstone in the management of heart failure with reduced ejection fraction (HFrEF) as they have been shown to improve survival and reduce hospitalizations.

## Why the Correct Answer is Right
Beta-blockers are started in patients with stable, optimally treated heart failure because they decrease the heart rate and contractility initially, which can worsen heart failure symptoms. The benefits of beta-blockade in heart failure are achieved through long-term use, where they help in reducing the sympathetic tone, slowing the heart rate, and decreasing the force of contraction, thereby reducing the workload on the heart. This leads to reverse remodeling and improved ejection fraction over time.

## Why Each Wrong Option is Incorrect
- **Option A:** Not provided, thus cannot be evaluated.
- **Option B:** Not provided, thus cannot be evaluated.
- **Option C:** Not provided, thus cannot be evaluated.
- **Option D:** Not provided, thus cannot be evaluated.

## Clinical Pearl / High-Yield Fact
A key clinical pearl is that beta-blockers should be initiated at a low dose in patients with stable heart failure and gradually up-titrated to target doses or to the maximum tolerated dose. This approach helps in minimizing the risk of initial worsening of heart failure symptoms.

## Correct Answer: D.